Phase I trial of targeted alpha-particle therapy using actinium-225 (Ac-225)-lintuzumab (anti-CD33) in combination with low-dose cytarabine (LDAC) for older patients with untreated acute myeloid leukemia (AML) Meeting Abstract

  


Authors: Jurcic, J. G.; Ravandi, F.; Pagel, J. M.; Park, J. H.; Smith, B. D.; Douer, D.; Estey, E. H.; Kantarjian, H. M.; Wahl, R. L.; Earle, D.; Cicic, D.; Scheinberg, D. A.
Abstract Title: Phase I trial of targeted alpha-particle therapy using actinium-225 (Ac-225)-lintuzumab (anti-CD33) in combination with low-dose cytarabine (LDAC) for older patients with untreated acute myeloid leukemia (AML)
Meeting Title: 56th Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 124
Issue: 21
Meeting Dates: 2014 Dec 6-9
Meeting Location: San Francisco, CA
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2014-12-06
Language: English
ACCESSION: WOS:000349242701171
PROVIDER: wos
DOI: 10.1182/blood.V124.21.5293.5293
Notes: Meeting Abstract: 5293 -- Source: Wos
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Jae Hong Park
    356 Park
  2. David Scheinberg
    499 Scheinberg
  3. Dan Douer
    87 Douer
Related MSK Work